Share Name Share Symbol Market Type Share ISIN Share Description
Biopharma Credit Plc LSE:BPCR London Ordinary Share GB00BDGKMY29 ORD USD0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 0.968 1,366,887 16:35:28
Bid Price Offer Price High Price Low Price Open Price
0.968 0.972 0.974 0.97 0.974
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Unknown 99.47 79.67 5.80 16.7 1,330
Last Trade Time Trade Type Trade Size Trade Price Currency
17:10:13 O 27 0.96814 USD

Biopharma Credit (BPCR) Latest News

More Biopharma Credit News
Biopharma Credit Investors    Biopharma Credit Takeover Rumours

Biopharma Credit (BPCR) Discussions and Chat

Biopharma Credit Forums and Chat

Date Time Title Posts
23/4/202116:50::: BIOPHARMA CREDIT PLC :::53

Add a New Thread

Biopharma Credit (BPCR) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Biopharma Credit trades in real-time

Biopharma Credit (BPCR) Top Chat Posts

Biopharma Credit Daily Update: Biopharma Credit Plc is listed in the Unknown sector of the London Stock Exchange with ticker BPCR. The last closing price for Biopharma Credit was US$0.97.
Biopharma Credit Plc has a 4 week average price of US$0.97 and a 12 week average price of US$0.96.
The 1 year high share price is US$1.03 while the 1 year low share price is currently US$0.93.
There are currently 1,373,872,373 shares in issue and the average daily traded volume is 1,389,358 shares. The market capitalisation of Biopharma Credit Plc is Ā£1,329,908,457.06.
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS:// As at the 31 March 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.85 cents. The Company's factsheet will be located on the Company's website, hxxp:// [28/2/21: 101.40 cents per share] [31/1/21: 100.84 cents per share] [31/12/20: 100.37 cents per share] [30/11/20: 99.91 cents per share] [31/10/20: 101.13 cents per share] [30/9/20: 101.00 cents per share]
davebowler: Liberum; $150m loan investment Mkt Cap £970m | Prem/(disc) -2.4% | Div yield 7.5% Event Biopharma Credit will invest $150m in a new loan with LumiraDX. The overall size of the facility is $300m with the remaining $150m provided by BioPharma V. The loan is for a term of three years with a fixed interest rate of 8%. The lenders will also receive fees of 4% (2.5% entry and 1.5% exit) and warrants as part of the transaction. LumiraDX is a point of care diagnostic company seeking to bring lab-comparable performance to point of care in minutes. To date, it has developed and launched four diagnostic tests for use with its platform including antigen test and antibody tests for Covid-19. The antigen tests are commercially available in the US and Europe. Existing customers for the antigen test include the NHS and CVS Pharmacy. The company has also started to roll out of a programme to supply Instruments and a significant number of Covid-19 antigen test strips to Africa as part of a collaboration with the Bill & Melinda Gates Foundation. Liberum view The new loan will represent 11% of NAV and will deploy the majority of the outstanding cash balance of $248m. The company received $425m of prepayments in H2 2020, which has led to an element of cash drag on returns in recent months. Prepayment fees and make-whole penalties have compensated for the cash drag and the new investment should add approximately 1 cent per share to recurring earnings (including annualised fees). This would ensure the dividend is broadly fully covered with the likelihood of additional improvements as further capital is deployed.
jonwig: Very satisfactory: "No material impact on the credit quality of any loan as a result of the global disruption caused by the Covid-19 pandemic". And they are throwing off dividends which is what we want. (Strictly speaking they are interest distributions and taxable outside an ISA. At 20% I think.)
speedsgh: "BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the period ending 31 December 2020 on Tuesday 16 March 2021."
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS:// As at the 31 January 2021 the unaudited net asset value per Ordinary Share, including current period revenue, was 100.84 cents. The Company's factsheet will be located on the Company's website, hxxp://
speedsgh: Net Asset Value(s) and Monthly Factsheet - HTTPS:// As at the 30 November 2020 the unaudited net asset value per Ordinary Share, including current period revenue, was 99.91 cents. The Company's factsheet and investor presentation will be located on the Company's website, hxxp://
speedsgh: Dividend Declaration - HTTPS:// BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, is pleased to declare an interim dividend in respect of the financial period ending 30 September 2020 of $0.0175 per ordinary share and a small special dividend in respect of the financial period ending 31 December 2019 of $0.0001 per ordinary share, payable on 18 December 2020 to ordinary shareholders on the register as at 20 November 2020. The Company has a small revenue reserve remaining for the fiscal year 2019 that it is distributing to ordinary shareholders. The Company has chosen to designate the entire amount of this interim and special dividend as an interest distribution. Shareholders in receipt of such a dividend will be treated for UK tax purposes as though they have received a payment of interest. This will result in a reduction in the corporation tax payable by the Company. The Company is currently paying and continues to target a 7 cent annual dividend per ordinary share.
speedsgh: ADDITIONAL INVESTMENT IN EPIZYME - HTTPS:// BioPharma Credit PLC (the "Company"), is pleased to announce that it, through its fully owned subsidiary, together with BioPharma Credit Investments V (Master) LP ("BioPharma-V" and jointly with the Company the "Lenders",) has entered into an amended and restated loan agreement with Epizyme, Inc ("Epizyme") dated 3 November 2020. As part of this amendment, the Company will invest an additional US$75 million in the Epizyme loan. Under the original terms of the loan agreement, executed in November 2019, Epizyme borrowed US$70 million in three tranches and the Company previously invested US$35 million with BioPharma-V investing the US$35 million balance. The original US$70 million loan will mature in November 2024 and bears interest at LIBOR plus 7.75 per cent. per annum along with a one-time additional consideration of 2.00 per cent. of the total loan amount. In addition, the facility was expandable by up to US$300 million, subject to mutual agreement between the Lenders and Epizyme after approval of tazemetostat for the treatment of follicular lymphoma. On 23 January 2020, TAZVERIKĀ® was granted accelerated approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with epithelioid sarcoma and on 18 June 2020 TAZVERIK received accelerated approval from the FDA for the treatment of patients with relapsed/refractory follicular lymphoma. The amendment increases the aggregate principal amount of the loan to Epizyme to US$220 million through a US$150 million fourth tranche ("Tranche D"), which the parties expect to be drawn in full on 18 November 2020. The Company will invest US$75 million of the US$150 million Tranche D and BioPharma-V will invest the US$75 million balance. Tranche D will have the same fees and coupon as the earlier tranches, will be secured by the same collateral as the earlier tranches, and will mature in November 2026 after eight equal amortization payments beginning in February 2025. As part of the amendment, the amortization terms of the initial US$70 million advanced in the first three tranches were changed from eight equal quarterly payments starting in February 2023 to four equal quarterly payments starting in February 2024. Following the expected Tranche D closing, the facility will remain expandable by up to an additional US$150 million, subject to mutual agreement between the Lenders and Epizyme. "We are delighted to expand our partnership with Epizyme", said Pedro Gonzalez de Cosio, CEO of Pharmakon Advisors, LP. "TAZVERIK is now approved to meet the well-defined unmet patient needs in two very different indications (a solid tumor and a hematologic malignancy), demonstrating its broad therapeutic potential." Further to the 4 November 2019 announcement of the original loan agreement, Royalty Pharma continues to hold approximately 9.1% of the issued share capital of Epizyme and Pablo Legorreta, a principal of Pharmakon and Royalty Pharma, continues to be a member of Epizyme's board of directors.
speedsgh: Director buys... On 30/9 Rolf Soderstrom (Director) bought 50,000 shares at £0.787344 = £39,367 HTTPS:// On 30/9 Linda Davey (PCA to Rolf Soderstrom, Director of BioPharma Credit PLC) bought 50,000 shares at £0.787344 = £39,367 HTTPS://
speedsgh: Half-year Report - HTTPS:// Pedro Gonzalez de Cosio, CEO and co-founder of Pharmakon Advisors L. P., the Investment Manager of BioPharma Credit PLC, said: "During the first six months of 2020, Covid-19 has brought exceptional challenges to the global economy resulting in volatile conditions for many sectors and a significant reduction in global dividends. However, as a result of the Company's uncorrelated revenue stream, dividend payments have continued uninterrupted towards the ongoing annual target of 7 cents per share, just above a 7% dividend yield to our investors on the 30 June share price. It is the Company's objective to continue to offer a highly attractive long-term source of income uncorrelated to other markets. "The Company's investment activity in deploying specialised debt investments such as senior secured loans backed by important life science products has continued as normal with one significant new investment in Collegium Pharmaceuticals during the period and additional follow-on commitments in addition to some attractive pre-payments post-period end. "The environment continues to be attractive for the Company's investment strategy given the considerable and growing capital needs of the sector. This will be potentially enhanced by an anticipated increase in sector M&A activity and a slowdown in equity issuance that has tended historically to lead to a greater appetite for fixed income as a source of capital for the life sciences industry."
Biopharma Credit share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Biopharma ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210516 21:08:29